Hussman Strategic Advisors Inc. Acquires New Shares in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Hussman Strategic Advisors Inc. purchased a new stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 16,800 shares of the company's stock, valued at approximately $1,353,000.

Several other large investors have also modified their holdings of PRCT. Creative Planning lifted its stake in PROCEPT BioRobotics by 88.9% in the 3rd quarter. Creative Planning now owns 9,948 shares of the company's stock valued at $797,000 after buying an additional 4,681 shares in the last quarter. Blue Trust Inc. lifted its position in shares of PROCEPT BioRobotics by 11.7% in the third quarter. Blue Trust Inc. now owns 4,441 shares of the company's stock valued at $356,000 after acquiring an additional 466 shares in the last quarter. International Assets Investment Management LLC lifted its position in shares of PROCEPT BioRobotics by 12,919.5% in the third quarter. International Assets Investment Management LLC now owns 52,078 shares of the company's stock valued at $4,172,000 after acquiring an additional 51,678 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its stake in shares of PROCEPT BioRobotics by 27.4% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 5,922 shares of the company's stock valued at $474,000 after acquiring an additional 1,273 shares during the last quarter. Finally, Values First Advisors Inc. purchased a new stake in PROCEPT BioRobotics during the 3rd quarter worth about $27,000. 89.46% of the stock is currently owned by institutional investors and hedge funds.

PROCEPT BioRobotics Stock Down 4.8 %

PRCT stock traded down $3.14 during mid-day trading on Friday, hitting $62.25. 1,465,542 shares of the company were exchanged, compared to its average volume of 861,542. The firm has a fifty day simple moving average of $76.53 and a 200 day simple moving average of $79.72. The company has a market capitalization of $3.25 billion, a PE ratio of -31.92 and a beta of 1.03. PROCEPT BioRobotics Co. has a twelve month low of $45.20 and a twelve month high of $103.81. The company has a current ratio of 6.02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21.

Insider Transactions at PROCEPT BioRobotics

In related news, CEO Reza Zadno sold 26,420 shares of the company's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $97.83, for a total transaction of $2,584,668.60. Following the sale, the chief executive officer now directly owns 179,185 shares of the company's stock, valued at approximately $17,529,668.55. This represents a 12.85 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Alaleh Nouri sold 28,092 shares of PROCEPT BioRobotics stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $97.13, for a total transaction of $2,728,575.96. Following the completion of the transaction, the executive vice president now directly owns 52,472 shares of the company's stock, valued at approximately $5,096,605.36. This represents a 34.87 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 80,935 shares of company stock valued at $7,882,089. Insiders own 17.40% of the company's stock.

Analyst Ratings Changes

A number of research analysts have issued reports on PRCT shares. Jefferies Financial Group began coverage on shares of PROCEPT BioRobotics in a report on Thursday, November 14th. They issued a "hold" rating and a $95.00 target price on the stock. Wells Fargo & Company reiterated an "overweight" rating and set a $112.00 target price on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. Morgan Stanley started coverage on PROCEPT BioRobotics in a report on Monday, December 2nd. They issued an "overweight" rating and a $105.00 price target for the company. Finally, Truist Financial reissued a "buy" rating and issued a $105.00 target price (up previously from $95.00) on shares of PROCEPT BioRobotics in a research note on Wednesday, October 30th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $97.86.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).